Edition:
United States

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,565.50GBp
21 Feb 2017
Change (% chg)

-4.50 (-0.10%)
Prev Close
4,570.00
Open
4,569.50
Day's High
4,602.00
Day's Low
4,558.50
Volume
1,221,999
Avg. Vol
3,213,989
52-wk High
5,505.00
52-wk Low
3,680.00

AZN.L

Chart for AZN.L

About

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease... (more)

Overall

Beta: 0.97
Market Cap(Mil.): £57,600.73
Shares Outstanding(Mil.): 1,265.28
Dividend: 150.20
Yield (%): --

Financials

  AZN.L Industry Sector
P/E (TTM): 20.52 28.39 29.32
EPS (TTM): 2.22 -- --
ROI: 7.52 13.54 13.03
ROE: 20.99 14.43 14.17

BRIEF-AstraZeneca sells U.S. Zoladex rights to tersera

* Enters agreement with tersera therapeutics for zoladex in us and canada

Feb 20 2017

AstraZeneca's Lynparza meets main goal in breast cancer study

Feb 17 AstraZeneca Plc said Lynparza, already approved to treat ovarian cancer, met the main goal of helping breast cancer patients live longer without their condition worsening in a late-stage study.

Feb 17 2017

Top AstraZeneca shareholder Woodford adds to stake, bullish on outlook

LONDON Top AstraZeneca shareholder Woodford Investment Management said on Wednesday it had added to its stake in the pharmaceutical firm and was confident in its growth outlook.

Feb 16 2017

REFILE-Top AstraZeneca shareholder Woodford adds to stake, bullish on outlook

LONDON, Feb 16 Top AstraZeneca shareholder Woodford Investment Management said on Wednesday it had added to its stake in the pharmaceutical firm and was confident in its growth outlook.

Feb 16 2017

BRIEF-Astrazeneca says will get $130 mln as milestone payment after Brodalumab approval

* Partner Valeant Pharmaceuticals announced that US FDA has approved Siliq (Brodalumab) injection for treatment of adult patients with moderate-to-severe plaque psoriasis

Feb 16 2017

BRIEF-Astrazeneca Plc reports a 4.5 percent passive stake in Catabasis Pharmaceuticals as of February 3, 2017

* Astrazeneca Plc reports a 4.5 percent passive stake in Catabasis Pharmaceuticals as of February 3, 2017 - SEC filing Source text : [ID:http://bit.ly/2lyYl4w] Further company coverage:

Feb 10 2017

BRIEF-Bachem Holding renews supply contract with AstraZeneca

* Renews supply contract with AstraZeneca for the peptide active substance Goserelin

Feb 07 2017

AstraZeneca flags tough 2017, yet confident on key cancer trial

LONDON AstraZeneca warned on Thursday that profit and revenue would both fall this year as cheap generic versions of its cholesterol drug Crestor continue to hit sales.

Feb 02 2017

UPDATE 4-AstraZeneca flags tough 2017, yet confident on key cancer trial

* Still confident on prospects for lung cancer trial (Adds more from CEO on cancer trial, long-term forecast, updates shares)

Feb 02 2017

AstraZeneca stands by 2023 sales above $40 billion at today's FX

LONDON AstraZeneca's chief executive remains confident in the drugmaker's ability to reach more than $40 billion in annual revenue in 2023, despite weakening sales of older medicines and uncertainty about those in the pipeline.

Feb 02 2017

More From Around the Web

Earnings vs. Estimates